NPX887 / NextPoint - LARVOL DELTA

Comprehensive analysis of B7-H7/HHLA2 expression in pan-solid tumors and its potential significance in anti-tumor immunity (AACR 2025) - P1 | "We demonstrated that normal tissue expression of B7-H7 is restricted to organ substructures within the intestine, lung, and kidney. We observed significant expression of B7-H7 across tumor cells of varying histologies, highlighting patient populations for B7-H7 targeting therapies. The IHC assay using E1U6X was selected for investigational use in ongoing (NPX887-001; NCT06240728) and potential future clinical studies of therapeutic molecules targeting the B7-H7 axis."

Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • HHLA2

A phase Ia/Ib dose-escalation/expansion study of NPX887 in subjects with solid tumor malignancies known to express HHLA2/B7-H7 (ESMO 2024) - P1 | "B7-H7 expression will be assessed by IHC from archival tissue and fresh biopsies to assess correlation with pharmacodynamic and clinical activity. A validated, clinical trial assay for B7-H7 will be used for prospective selection of participants in phase 1b."

Clinical • IO biomarker • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HHLA2 • PD-L1

Targeting HHLA2-mediated immunosuppression with NPX267 and NPX887, two fully human monoclonal antibodies that target KIR3DL3 and HHLA2 respectively (CIMT 2024) - P1 | "Additionally, HHLA2 represents a novel tumor target with limited normal tissue expression. NPX267 and NPX887 are currently being evaluated in Phase I clinical trials for patients with solid tumors known to express HHLA2 / B7-H7 [NCT05958199] and [NCT06240728] respectively."

Oncology • Solid Tumor • HHLA2 • KIR2DS2

NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors (Businesswire) - "NextPoint Therapeutics...announced today that the first patient has been dosed with NPX887 in a Phase 1 first-in-human clinical trial for the treatment of patients with solid tumors expressing HHLA2/B7-H7, a tumor antigen strongly upregulated in many human tumors independently of PD-L1. The study is a Phase 1a/1b open-label, multi-center trial (NCT06240728) consisting of a dose escalation and an expansion stage to evaluate the tolerability, pharmacokinetics, immunogenicity and biomarker-based selection of NPX887 in patients with solid tumor malignancies including non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC) and other solid tumor types known to express HHLA2/B7-H7."

Trial status • Colorectal Cancer • Non Small Cell Lung Cancer • Renal Cell Carcinoma

NPX887-001: A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA-2/B7-H7 (clinicaltrials.gov) - P1 | N=144 | Recruiting | Sponsor: NextPoint Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

NPX887-001: A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA-2/B7-H7 (clinicaltrials.gov) - P1 | N=144 | Not yet recruiting | Sponsor: NextPoint Therapeutics, Inc.

New P1 trial • Oncology • Solid Tumor

NextPoint Therapeutics Announces IND Clearance from the FDA to Advance NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors (Businesswire) - "NextPoint Therapeutics...announced the acceptance of its investigational new drug (IND) application by the U.S. Food & Drug Administration (FDA) for NPX887. The company plans to initiate a first-in-human Phase I clinical trial in early 2024 evaluating NPX887 in patients with solid tumors known to express HHLA2, a tumor antigen strongly upregulated in many human cancers."

IND • New P1 trial • Solid Tumor